3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh (mirikizumab) for ulcerative colitis on 29 August 2024, with a letter of intent. 

Omvoh is the first and only interleukin-23p19 antagonist approved in Canada for the treatment of moderately to severely active ulcerative colitis and is indicated for adult ulcerative colitis patients who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase inhibitor.

Read Eli Lilly press release